In Europe, 25,000 deaths were reported in 2007 as a result of antimicrobial resistance, with two thirds of these deaths due to Gram-negative bacteria. Most troublesome is the rapid emergence and spread of resistance to third generation cephalosporins in E. coli and K. pneumoniae. Prompt action is therefore a clear priority.

Visit the project website


Combatting Bacterial Resistance in Europe – Molecules Against Gram Negative Infections

COMBACT-MAGNET is a consortium of researchers from four pharmaceutical companies, and over thirty leading academic medical centers from ten European countries  focusing on the most vulnerable category of patients: those who are critically ill and being treated in intensive-care units. Penta is a paediatric partner in the consortium and will be involved in the coordination of upcoming clinical studies among neonates in intensive care.

Why is COMBACT-MAGNET needed?

Antimicrobial resistance (AMR) is a major global public health threat. In 2011, the European Centre for Disease Prevention and Control (ECDC) antimicrobial resistance surveillance reported a general increase of resistance in the European Gram-negative pathogens under surveillance. Such infections are frequently associated with increases in mortality, morbidity, and length of hospitalisation. 

What is COMBAT-MAGNET’s goal?

The COMBACTE-MAGNET consortium will provide groundbreaking multinational phase 2 and phase 3 studies in adult intensive care unit (ICU) patients and a phase 1 paediatric safety and PK study with the bispecific immunoglobulin (IgG)1 mAb (MEDI3902) targeting the pathogenic components PsI and PcrV as a new approach for preventing P. aeruginosa infections, especially pulmonary infections, in ICU patients.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme and EFPIA companies in kind contribution.